Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2010, Vol. 4 Issue (4) : 399-411     DOI: 10.1007/s11684-010-0170-y
Research articles |
Dysregulation of β-catenin by hepatitis B virus X protein in HBV-infected human hepatocellular carcinomas
Lei CHEN1,Liang HU1,Liang LI1,Yuan LIU1,Qian-Qian TU1, Yan-Xin CHANG1,He-Xin YAN1,Meng-Chao WU2, Hong-Yang WANG3,
1.International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China; 2.Second Military Medical University, Shanghai 200438, China; 3.International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438, China;National Laboratory for Oncogenes and Related Genes, Key Lab of Cancer Institute in Renji Hospital, Shanghai Jiao-Tong University, Shanghai 200441, China;
Download: PDF(876 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  β-catenin is a key molecule involved in both cell-cell adhesion and Wnt signaling pathway. In our study, we found that, in the development of hepatocellular carcinoma (HCC), β-catenin was correlated with hepatitis B virus (HBV) X gene encoded protein, which is essential for HBV infectivity and is a potential cofactor in viral carcinogenesis. The expression levels of wild-type β-catenin and E-cadherin were decreased in HepG2 cells expressing hepatitis B virus X protein (HBx), accompanied by destabilization of adherens junction. Reverse transcriptase PCR (RT-PCR), Northern and Western blot showed that reduction of wild-type β-catenin expression involved degradation of the protein. However, RNA interference (RNAi) and luciferase assay indicated that HBx enhanced β-catenin mediated signaling in HepG2 cells. In addition, immunohistochemical and Western blot analysis of β-catenin revealed that a decrease in the β-catenin protein level was found in 58.3% of HBV-related HCCs versus 19.2% of non-HBV-related tumors. Our data suggest that the expression of HBx contributed to the development of HCC, in part, by repressing the wild-type β-catenin expression and enforcing β-catenin-dependent signaling pathway, thus inducing cellular changes leading to acquisition of metastatic and/or proliferation properties.
Keywords hepatocellular carcinoma      hepatitis B virus X protein      β-catenin      cell adhesion      E-cadherin      transcriptional activation      
Issue Date: 05 December 2010
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0170-y     OR     http://academic.hep.com.cn/fmd/EN/Y2010/V4/I4/399
Schafer D F, Sorrell M F. Hepatocellular carcinoma. Lancet, 1999, 353(9160): 1253–1257
PMID: 10217098
Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, Dejean A. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected bycomparative genomic hybridization. Genes Chromosomes Cancer, 1997, 18(1): 59–65
PMID: 8993981
Feitelson M A, Duan L X. Hepatitis B virus X antigen in the pathogenesis of chronic infections and thedevelopment of hepatocellular carcinoma. Am J Pathol, 1997, 150(4): 1141–1157
PMID: 9094970
Su Q, Schr?der C H, Hofmann W J, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis Bvirus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology, 1998, 27(4): 1109–1120
PMID: 9537452
Kim C M, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virusinduces liver cancer in transgenic mice. Nature, 1991, 351(6324): 317–320
PMID: 2034275
Slagle B L, Lee T H, Medina D, Finegold M J, Butel J S. Increased sensitivity tothe hepatocarcinogen diethylnitrosamine in transgenic mice carryingthe hepatitis B virus X gene. Mol Carcinog, 1996, 15(4): 261–269
PMID: 8634084
Terradillos O, Billet O, Renard C A, Levy R, Molina T, Briand P, Buendia M A. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesisin transgenic mice. Oncogene, 1997, 14(4): 395–404
PMID: 9053836
Benn J, Schneider R J. Hepatitis B virus HBx protein activates Ras-GTP complex formationand establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci U S A, 1994, 91(22): 10350–10354
PMID: 7937954
Natoli G, Avantaggiati M L, Chirillo P, Puri P L, Ianni A, Balsano C, Levrero M. Ras- and Raf-dependent activation of c-jun transcriptional activityby the hepatitis B virus transactivator pX. Oncogene, 1994, 9(10): 2837–2843
PMID: 8084589
Su F, Schneider R J. Hepatitis B virus HBx protein activates transcription factor NF-kappaBby acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol, 1996, 70(7): 4558–4566
PMID: 8676482
Benn J, Su F, Doria M, Schneider R J. Hepatitis B virus HBx protein induces transcription factor AP-1 byactivation of extracellular signal-regulated and c-Jun N-terminalmitogen-activated protein kinases. J Virol, 1996, 70(8): 4978–4985
PMID: 8764004
Mahé Y, Mukaida N, Kuno K, Akiyama M, Ikeda N, Matsushima K, Murakami S. Hepatitis B virus X protein transactivates human interleukin-8gene through acting on nuclear factor kB and CCAAT/enhancer-bindingprotein-like cis-elements. J Biol Chem, 1991, 266(21): 13759–13763
PMID: 1856209
Gottlob K, Fulco M, Levrero M, Graessmann A. The hepatitis B virus HBx protein inhibits caspase 3 activity. J Biol Chem, 1998, 273(50): 33347–33353
PMID: 9837909
Lee T H, Elledge S J, Butel J S. Hepatitis B virus X proteininteracts with a probable cellular DNA repair protein. J Virol, 1995, 69(2): 1107–1114
PMID: 7815490
Ueda H, Ullrich S J, Gangemi J D, Kappel C A, Ngo L, Feitelson M A, Jay G. Functional inactivation but not structural mutation ofp53 causes liver cancer. Nat Genet, 1995, 9(1): 41–47
PMID: 7704023
Tlsty T D. Cell-adhesion-dependent influences on genomic instabilityand carcinogenesis. Curr Opin Cell Biol, 1998, 10(5): 647–653
PMID: 9818176
Kemler R. From cadherins to catenins: cytoplasmic protein interactionsand regulation of cell adhesion. Trends Genet, 1993, 9(9): 317–321
PMID: 8236461
Kozyraki R, Scoazec J Y, Flejou J F, D'Errico A, Bedossa P, Terris B, Fiorentino M, Bringuier A F, Grigioni W F, Feldmann G. Expression of cadherins and alpha-catenin in primaryepithelial tumors of the liver. Gastroenterology, 1996, 110(4): 1137–1149
PMID: 8613003
Wei Y, Van Nhieu J T, Prigent S, Srivatanakul P, Tiollais P, Buendia M A. Altered expression of E-cadherinin hepatocellular carcinoma: correlations with genetic alterations,β-catenin expression, and clinical features. Hepatology, 2002, 36(3): 692–701
PMID: 12198663
Peifer M. β-catenin as oncogene: the smoking gun. Science, 1997, 275(5307): 1752–1753
PMID: 9122680
Moon R T, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through β-catenin. Science, 2002, 296(5573): 1644–1646
PMID: 12040179
He T C, Sparks A B, Rago C, Hermeking H, Zawel L, da Costa L T, Morin P J, Vogelstein B, Kinzler K W. Identification of c-MYC as a target of the APC pathway. Science, 1998, 281(5382): 1509–1512
PMID: 9727977
Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinomacells. Nature, 1999, 398(6726): 422–426
PMID: 10201372
Liu C, Li Y, Semenov M, Han C, Baeg G H, Tan Y, Zhang Z, Lin X, He X. Control of β-catenin phosphorylation/degradation by a dual-kinasemechanism. Cell, 2002, 108(6): 837–847
PMID: 11955436
Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell, 2000, 103(2): 311–320
PMID: 11057903
de La Coste A, Romagnolo B, Billuart P, Renard C A, Buendia M A, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellularcarcinomas. Proc Natl Acad Sci U S A, 1998, 95(15): 8847–8851
PMID: 9671767
Samowitz W S, Powers M D, Spirio L N, Nollet F, van Roy F, Slattery M L. β-catenin mutations are more frequent in small colorectaladenomas than in larger adenomas and invasive carcinomas. Cancer Res, 1999, 59(7): 1442–1444
PMID: 10197610
Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associatedwith hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 2001, 120(7): 1763–1773
PMID: 11375957
Hsu H C, Jeng Y M, Mao T L, Chu J S, Lai P L, Peng S Y. β-catenin mutations are associated with a subsetof low-stage hepatocellular carcinoma negative for hepatitis B virusand with favorable prognosis. Am J Pathol, 2000, 157(3): 763–770
PMID: 10980116
Huang H, Fujii H, Sankila A, Mahler-Araujo B M, Matsuda M, Cathomas G, Ohgaki H. β-catenin mutations are frequent in human hepatocellular carcinomas associatedwith hepatitis C virus infection. Am J Pathol, 1999, 155(6): 1795–1801
PMID: 10595907
Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomasfrequently carry a mutated degradation targeting box of the β-cateningene. Cancer Res, 1999, 59(2): 269–273
PMID: 9927029
Lian Z, Liu J, Pan J, Satiroglu Tufan N L, Zhu M, Arbuthnot P, Kew M, Clayton M M, Feitelson M A. A cellular gene up-regulated by hepatitis B virus-encodedX antigen promotes hepatocellular growth and survival. Hepatology, 2001, 34(1): 146–157
PMID: 11431746
Lian Z, Pan J, Liu J, Zhang S, Zhu M, Arbuthnot P, Kew M, Feitelson M A. The translation initiationfactor, hu-Sui1 may be a target of hepatitisB X antigen in hepatocarcinogenesis. Oncogene, 1999, 18(9): 1677–1687
PMID: 10208429
Yan H X, He Y Q, Dong H, Zhang P, Zeng J Z, Cao H F, Wu M C, Wang H Y. Physical and functional interaction betweenreceptor-like protein tyrosine phosphatase PCP-2 and β-catenin. Biochemistry, 2002, 41(52): 15854–15860
PMID: 12501215
Andrews N C, Faller D V. A rapid micropreparation technique for extraction of DNA-binding proteinsfrom limiting numbers of mammalian cells. Nucleic Acids Res, 1991, 19(9): 2499–2506
PMID: 2041787
Wang H, Lian Z, Lerch M M, Chen Z, Xie W, Ullrich A. Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family. Oncogene, 1996, 12(12): 2555–2562
PMID: 8700514
Carruba G, Cervello M, Miceli M D, Farruggio R, Notarbartolo M, Virruso L, Giannitrapani L, Gambino R, Montalto G, Castagnetta L. Truncated form of β-catenin and reduced expressionof wild-type catenins feature HepG2 human liver cancer cells. Ann N Y Acad Sci, 1999, 886: 212–216
PMID: 10667222
Su Q, Schr?der C H, Hofmann W J, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis Bvirus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology, 1998, 27(4): 1109–1120
PMID: 9537452
Wang W L, London W T, Feitelson M A. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res, 1991, 51(18): 4971–4977
PMID: 1654208
Huber A H, Stewart D B, Laurents D V, Nelson W J, Weis W I. The cadherin cytoplasmic domain is unstructured in the absence of β-catenin.A possible mechanism for regulating cadherin turnover. J Biol Chem, 2001, 276(15): 12301–12309
PMID: 11121423
Polakis P. The oncogenic activation of β-catenin. Curr Opin Genet Dev, 1999, 9(1): 15–21
PMID: 10072352
Gottardi C J, Wong E, Gumbiner B M. E-cadherin suppresses cellulartransformation by inhibiting β-catenin signaling in an adhesion-independentmanner. J Cell Biol, 2001, 153(5): 1049–1060
PMID: 11381089
Staal F J, Noort Mv M, Strous G J, Clevers H C. Wnt signals are transmitted through N-terminally dephosphorylatedβ-catenin. EMBO Rep, 2002, 3(1): 63–68
PMID: 11751573
[1] Xinsen Xu,Yanyan Zhou,Runchen Miao,Wei Chen,Kai Qu,Qing Pang,Chang Liu. Transcriptional modules related to hepatocellular carcinoma survival: coexpression network analysis[J]. Front. Med., 2016, 10(2): 183-190.
[2] Zhi Xu,Chunxiang Cao,Haiyan Xia,Shujing Shi,Lingzhi Hong,Xiaowei Wei,Dongying Gu,Jianmin Bian,Zijun Liu,Wenbin Huang,Yixin Zhang,Song He,Nikki Pui-Yue Lee,Jinfei Chen. Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma[J]. Front. Med., 2016, 10(1): 52-60.
[3] Felice Ho-Ching Tsang,Sandy Leung-Kuen Au,Lai Wei,Dorothy Ngo-Yin Fan,Joyce Man-Fong Lee,Carmen Chak-Lui Wong,Irene Oi-Lin Ng,Chun-Ming Wong. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility[J]. Front. Med., 2015, 9(3): 331-343.
[4] Farhad Sahebjam,John M. Vierling. Autoimmune hepatitis[J]. Front. Med., 2015, 9(2): 187-219.
[5] Guanghua Rong,Wenlin Bai,Zheng Dong,Chunping Wang,Yinying Lu,Zhen Zeng,Jianhui Qu,Min Lou,Hong Wang,Xudong Gao,Xiujuan Chang,Linjing An,Yan Chen,Yongping Yang. Cryotherapy for cirrhosis-based hepatocellular carcinoma: a single center experience from 1595 treated cases[J]. Front. Med., 2015, 9(1): 63-71.
[6] Marielle Reataza,David K. Imagawa. Advances in managing hepatocellular carcinoma[J]. Front. Med., 2014, 8(2): 175-189.
[7] Kai Qu,Ting Lin,Zhixin Wang,Sinan Liu,Hulin Chang,Xinsen Xu,Fandi Meng,Lei Zhou,Jichao Wei,Minghui Tai,Yafeng Dong,Chang Liu. Reactive oxygen species generation is essential for cisplatin-induced accelerated senescence in hepatocellular carcinoma[J]. Front. Med., 2014, 8(2): 227-235.
[8] Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen. Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk[J]. Front. Med., 2014, 8(2): 217-226.
[9] Feng Ye, Adam K. Snider, Mark H. Ginsberg. Talin and kindlin: the one-two punch in integrin activation[J]. Front Med, 2014, 8(1): 6-16.
[10] Carmen Chak-Lui Wong, Alan Ka-Lun Kai, Irene Oi-Lin Ng. The impact of hypoxia in hepatocellular carcinoma metastasis[J]. Front Med, 2014, 8(1): 33-41.
[11] Lunxiu Qin. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies[J]. Front Med, 2014, 8(1): 24-32.
[12] Beicheng Sun, Michael Karin. Inflammation and liver tumorigenesis[J]. Front Med, 2013, 7(2): 242-254.
[13] Shuangwei Li, Diane DiFang Hsu, Hongyang Wang, Gen-Sheng Feng. Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis[J]. Front Med, 2012, 6(3): 275-279.
[14] Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan. Translational medicine in hepatocellular carcinoma[J]. Front Med, 2012, 6(2): 122-133.
[15] Xi Feng, Madhava Pai, Malkhaz Mizandari, Tinatin Chikovani, Duncan Spalding, Long Jiao, Nagy Habib. Towards the optimization of management of hepatocellular carcinoma[J]. Front Med, 2011, 5(3): 271-276.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed